Bruker, HealthLinx File Patents for Biomarkers Linked to Pregnancy Risk | GenomeWeb
NEW YORK (GenomeWeb News) — Bruker Daltonics and HealthLinx have filed a joint PCT patent application to develop and market diagnostics based on their joint discovery of two biomarkers linked to pregnancy complications, HealthLinx said today.
The tests will be based on Bruker’s ClinProt test, but HealthLinx said it will retain the rights to any ELISA/multiplex tests developed from these patents in the future.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.